Applied DNA Sciences Cash Flow - Quarterly (NASDAQ:APDN)

Add to My Stocks
$1.6 $0.03 (1.91%) APDN stock closing price Mar 16, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Applied DNA Sciences needs to disclose. The profit-loss statement shows Applied DNA Sciences profits, the balance sheet shows Applied DNA Sciences debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Applied DNA Sciences had cash and cash equivalents of $4.47M at beginning of the quarter and $4.76M at quarter end of 2018 Q1. Applied DNA Sciences cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. APDN decrease in investments stood at a value of $-0.05M for the latest quarter 2018 Q1.

View and download details of Applied DNA Sciences cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Oct - Sep2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities------0.67M--0.21M-0.47M-3.74M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-3.93M2.93M2.01M1.46M2.24M1.63M--8.16M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.05M-0.14M-0.11M-0.09M-0.04M-0.66M-0.58M-0.12M-0.05M-1.85M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities------0.11M-0.04M-0.03M-0.01M-0.28M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares4.43M6.1M4.6M4.33M4.33M7.85M7.85M7.85M7.85M15.02M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities------0.01M----
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year4.47M7.31M1.39M6.36M-2.74M----
Cash & Equivalents at Year End4.76M2.95M2.4M4.02M6.7M4.47M7.08M9.78M12.38M7.31M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Applied DNA Sciences stock price history and Applied DNA Sciences stock comparison chart inevitably reflect its cash flow situation.

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Applied DNA Sciences is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Applied DNA Sciences stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-2.57M for APDN.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-0.05M for APDN stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $4.43M for Applied DNA Sciences.

Key Financial Ratios For Applied DNA Sciences Cash Flow

Quarterly Cash Flow Statements For Applied DNA Sciences Inc Peers

Alpha Pro Tech cash flow, Ascent Capital cash flow, Covisint cash flow, SuperCom cash flow